Gross Margin % is calculated as gross profit divided by its revenue. Surmodics's Gross Profit for the
three
months ended in Jun. 2025 was $13.4 Mil. Surmodics's Revenue for the
three
months ended in Jun. 2025 was $29.6 Mil. Therefore, Surmodics's Gross Margin % for the quarter that ended in Jun. 2025 was 45.38%.
The historical rank and industry rank for Surmodics's Gross Margin % or its related term are showing as below:
SRDX'
s Gross Margin % Range Over the Past 10 Years
Min: 29.01 Med: 40.04 Max: 59.96
Current: 44.46
During the past 13 years, the highestGross Margin % of Surmodics was 59.96%. The lowest was 29.01%. And the median was 40.04%.
SRDX's Gross Margin % is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 52.07
vs SRDX: 44.46
Surmodics had a gross margin of 45.38% for the quarter that ended in Jun. 2025 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Surmodics was 6.40% per year.
Surmodics (NAS:SRDX) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Surmodics had a gross margin of 45.38% for the quarter that ended in Jun. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Surmodics Gross Margin % Related Terms
Surmodics Gross Margin % Historical Data
* Premium members only.
The historical data trend for Surmodics's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SRDX vs CBLL, OFIX, LAB: Gross Margin % Comparison
For the Medical Devices subindustry, Surmodics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Surmodics Gross Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Surmodics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Surmodics's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Surmodics (SRDX) has a Gross Margin % of 45.38% as of Jun. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Surmodics and its competitors. This is 13% above median its historical median of 40.04. Over the past decade, Surmodics' Gross Margin % has ranged from 29.01 to 59.96.
Is Surmodics' Gross Margin % too high?
Surmodics' current Gross Margin % of 45.38% is 13% above median its 10-year median of 40.04. Over the past 10 years, this metric has ranged from a low of 29.01 to a high of 59.96. The Medical Devices & Instruments industry median Gross Margin % is 52.07. Surmodics' value of 45.38% is 12.8% below this industry median. Overall, Surmodics has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does Surmodics' Gross Margin % compare to CBLL and OFIX?
Surmodics' Gross Margin % of 45.38% can be compared against companies in the Medical Devices & Instruments industry. The industry median Gross Margin % is 52.07. Surmodics' value of 45.38% is 12.8% below this benchmark. Historically, Surmodics' own Gross Margin % has ranged from 29.01 to 59.96 over the past decade. While the company's 10-year median is 40.04 vs. the industry median of 52.07, Surmodics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Devices & Instruments company?
The median Gross Margin % among Medical Devices & Instruments companies is 52.07, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Surmodics's current Gross Margin % of 45.38% is 12.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Surmodics and its competitors. For the Medical Devices & Instruments industry, the median Gross Margin % is 52.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Surmodics's current Gross Margin % is 45.38%, which is 13% above median its own 10-year median of 40.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Surmodics stock overvalued right now?
Surmodics (SRDX) has a current Gross Margin % of 45.38%. The stock's GF Value™ is $32.10, compared to a current price of $42.98 — trading 33.9% above its estimated fair value. The current Gross Margin % is 45.38%, which is 13% above median its 10-year median of 40.04 and 12.8% below the Medical Devices & Instruments industry median of 52.07. Surmodics' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Surmodics (SRDX), the current Gross Margin % is 45.38% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Surmodics (SRDX) Overvalued in 2026?
Based on GuruFocus' analysis, Surmodics stock appears to be overvalued.
The current stock price of $42.98 is trading 33.9% above its estimated GF Value™ of $32.10.
Key valuation signals for SRDX:
Gross Margin %: 45.38% (13% above median its 10-year median of 40.04)
GF Value™: $32.10 vs. price of $42.98 (33.9% above fair value)
Industry Position: 12.8% below the Medical Devices & Instruments median
No single metric tells the full story. See the SRDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Surmodics Inc is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The company's reportable segments are; Medical Device and In Vitro Diagnostics. Maximum revenue for the company is derived from its Medical Device segment which is involved in the manufacturing and licensing of performance coatings, including surface modification coating technologies and drug-delivery coating technologies. This segment also manufactures vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. Geographically, the company derives key revenue from its domestic market.
51GF Score
Get the complete analysis for SRDX
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SRDX has been successfully added to your 
